BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13(28): 3806-3815 [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Shuayb M, Mehedi Hasan M, Hoque MR, Mushtaq Hussain Q, Begum R, Reza MS. Survival and prognostic association in stage IV colorectal cancer patients treated with chemotherapy in Bangladesh. Jpn J Clin Oncol 2021;51:552-9. [PMID: 33341898 DOI: 10.1093/jjco/hyaa228] [Reference Citation Analysis]
2 王士勇, 杨振君, 于环, 杜微丽, 刘飒, 张哲, 张远, 邓英杰. β-榄香烯脂质体体内外对消化系肿瘤的抑制作用. 世界华人消化杂志 2008; 16(10): 1059-1063 [DOI: 10.11569/wcjd.v16.i10.1059] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871 [PMID: 25110417 DOI: 10.3748/wjg.v20.i29.9862] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
4 Xie J, Chen L, Chen W. High NUCB2 expression level is associated with metastasis and may promote tumor progression in colorectal cancer. Oncol Lett 2018;15:9188-94. [PMID: 29805650 DOI: 10.3892/ol.2018.8523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Wang N, Zeng L, Li Z, Zhen Y, Chen H. Serum miR-663 expression and the diagnostic value in colorectal cancer. Artif Cells Nanomed Biotechnol 2019;47:2650-3. [PMID: 31240955 DOI: 10.1080/21691401.2019.1628036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Xynos ID, Kavantzas N, Tsaousi S, Zacharakis M, Agrogiannis G, Kosmas C, Lazaris A, Sarantonis J, Sougioultzis S, Tzivras D, Polyzos A, Patsouris ES, Tsavaris N. Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy. ISRN Gastroenterol 2013;2013:490578. [PMID: 23840958 DOI: 10.1155/2013/490578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
7 Richman SD, Hutchins GG, Seymour MT, Quirke P. What can the molecular pathologist offer for optimal decision making? Ann Oncol 2010;21 Suppl 7:vii123-9. [PMID: 20943604 DOI: 10.1093/annonc/mdq379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
8 Tomita Y, Karapetis CS, Ullah S, Townsend AR, Roder D, Beeke C, Roy AC, Padbury R, Price TJ. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncol 2016;55:480-5. [PMID: 26878155 DOI: 10.3109/0284186X.2015.1117135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
9 Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, Shinden Y, Eguchi H, Yamamoto H, Doki Y, Mori M, Ochiya T, Mimori K. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113:275-281. [PMID: 26057451 DOI: 10.1038/bjc.2015.201] [Cited by in Crossref: 275] [Cited by in F6Publishing: 274] [Article Influence: 45.8] [Reference Citation Analysis]
10 Kelly KJ, Wong J, Fong Y. Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 2008;17:1105-13. [PMID: 18549346 DOI: 10.1517/13543784.17.7.1105] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
11 De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
12 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
13 Liu X, Chu Y, Wang D, Weng Y, Jia Z. MAPK-mediated upregulation of fibrinogen-like protein 2 promotes proliferation, migration, and invasion of colorectal cancer cells. Cell Biol Int 2019. [PMID: 31286589 DOI: 10.1002/cbin.11198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cameron S, Hünerbein D, Mansuroglu T, Armbrust T, Scharf JG, Schwörer H, Füzesi L, Ramadori G. Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy. BMC Cancer 2009;9:218. [PMID: 19570230 DOI: 10.1186/1471-2407-9-218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Mallawaaratchy DM, Mactier S, Kaufman KL, Blomfield K, Christopherson RI. The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. J Proteomics 2012;75:1590-9. [PMID: 22172953 DOI: 10.1016/j.jprot.2011.11.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
16 Castillo-Fernández O, Santibáñez M, Bauza A, Calderillo G, Castro C, Herrera R, Serrano A, Arrieta O, Herrera LA. Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res 2010;41:430-5. [PMID: 21044746 DOI: 10.1016/j.arcmed.2010.08.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
17 Pudova EA, Kudryavtseva AV, Fedorova MS, Zaretsky AR, Shcherbo DS, Lukyanova EN, Popov AY, Sadritdinova AF, Abramov IS, Kharitonov SL, Krasnov GS, Klimina KM, Koroban NV, Volchenko NN, Nyushko KM, Melnikova NV, Chernichenko MA, Sidorov DV, Alekseev BY, Kiseleva MV, Kaprin AD, Dmitriev AA, Snezhkina AV. HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer. BMC Genomics. 2018;19:113. [PMID: 29504907 DOI: 10.1186/s12864-018-4477-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
18 Miao W, Wang Y. Targeted Quantitative Kinome Analysis Identifies PRPS2 as a Promoter for Colorectal Cancer Metastasis. J Proteome Res 2019;18:2279-86. [PMID: 30908912 DOI: 10.1021/acs.jproteome.9b00119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
19 Wang LJ, Zhang ZY, Yan XL, Yang W, Yan K, Xing BC. Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis. World J Surg Oncol 2018;16:207. [PMID: 30322402 DOI: 10.1186/s12957-018-1494-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
20 Wu Q, Zhang P, Wang X, Zhang M, Liao W, Li Q. Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. Clinical Therapeutics 2020;42:2148-2158.e2. [DOI: 10.1016/j.clinthera.2020.08.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M, Garcia-Larnicol ML, Dumont S, Louvet C, Perez-Staub N, Hadengue A, de Gramont A, Bonnetain F. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Health Qual Life Outcomes 2014;12:69. [PMID: 24886671 DOI: 10.1186/1477-7525-12-69] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
22 Silvestri A, Calvert V, Belluco C, Lipsky M, De Maria R, Deng J, Colombatti A, De Marchi F, Nitti D, Mammano E, Liotta L, Petricoin E, Pierobon M. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. Clin Exp Metastasis 2013;30:309-16. [PMID: 23053743 DOI: 10.1007/s10585-012-9538-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liang XH, Zhang GX, Zeng YB, Yang HF, Li WH, Liu QL, Tang YL, He WG, Huang YN, Zhang L, Yu LN, Zeng XC. LIM protein JUB promotes epithelial-mesenchymal transition in colorectal cancer. Cancer Sci 2014;105:660-6. [PMID: 24673742 DOI: 10.1111/cas.12404] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ding C, Tang W, Fan X, Wu G. Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics. Onco Targets Ther 2018;11:4797-810. [PMID: 30147331 DOI: 10.2147/OTT.S170626] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
25 Frank F, Hecht M, Loy F, Rutzner S, Fietkau R, Distel L. Differences in and Prognostic Value of Quality of Life Data in Rectal Cancer Patients with and without Distant Metastases. Healthcare (Basel) 2020;9:E1. [PMID: 33374955 DOI: 10.3390/healthcare9010001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Park J, Jang JH, Kim JH. Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells. Biochim Biophys Acta Mol Cell Res 2019;1866:329-36. [PMID: 30553812 DOI: 10.1016/j.bbamcr.2018.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Chua TC, Saxena A, Liauw W, Chu F, Morris DL. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review. Eur J Cancer. 2012;48:1757-1765. [PMID: 22153217 DOI: 10.1016/j.ejca.2011.10.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
28 Lee YM, Kaduwal S, Lee KH, Park JC, Jeong WJ, Choi KY. Sur8 mediates tumorigenesis and metastasis in colorectal cancer. Exp Mol Med 2016;48:e249. [PMID: 27469030 DOI: 10.1038/emm.2016.58] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rashidi SK, Mousavi Gargari SL, Ebrahimizadeh W. Targeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target. Iran J Biotechnol 2017;15:78-86. [PMID: 29845054 DOI: 10.15171/ijb.1472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Cheung FP, Alam NZ, Wright GM. The Past, Present and Future of Pulmonary Metastasectomy: A Review Article. Ann Thorac Cardiovasc Surg 2019;25:129-41. [PMID: 30971647 DOI: 10.5761/atcs.ra.18-00229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
31 Harmse L, Gangat N, Martins-Furness C, Dam J, de Koning CB. Copper-imidazo[1,2-a]pyridines induce intrinsic apoptosis and modulate the expression of mutated p53, haem-oxygenase-1 and apoptotic inhibitory proteins in HT-29 colorectal cancer cells. Apoptosis 2019;24:623-43. [PMID: 31073781 DOI: 10.1007/s10495-019-01547-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ding C, Li L, Yang T, Fan X, Wu G. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer 2016;16:791. [PMID: 27729020 DOI: 10.1186/s12885-016-2834-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
33 Sarafan-Vasseur N, Sefrioui D, Tougeron D, Lamy A, Blanchard F, Le Pessot F, Di Fiore F, Michel P, Bézieau S, Latouche JB, Frebourg T, Sesboüé R. Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer. BMC Cancer 2013;13:183. [PMID: 23565769 DOI: 10.1186/1471-2407-13-183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Chen TL, Lin YW, Chen YB, Lin JJ, Su TL, Shen CN, Lee TC. A Low-Toxicity DNA-Alkylating N-Mustard-Quinoline Conjugate with Preferential Sequence Specificity Exerts Potent Antitumor Activity Against Colorectal Cancer. Neoplasia 2018;20:119-30. [PMID: 29247884 DOI: 10.1016/j.neo.2017.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
35 Engelhardt EG, Révész D, Tamminga HJ, Punt CJ, Koopman M, Onwuteaka-philipsen BD, Steyerberg EW, Jansma IP, De Vet HC, Coupé VM. Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review. Clinical Colorectal Cancer 2018;17:e1-e12. [DOI: 10.1016/j.clcc.2017.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
36 Pietrzyk Ł, Wdowiak P. Serum TEM5 and TEM7 concentrations correlate with clinicopathologic features and poor prognosis of colorectal cancer patients. Advances in Medical Sciences 2019;64:402-8. [DOI: 10.1016/j.advms.2019.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res. 2013;19:3987-3995. [PMID: 23743569 DOI: 10.1158/1078-0432.ccr-13-0027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
38 Roshanaei G, Safari M, Faradmal J, Abbasi M, Khazaei S. Factors affecting the survival of patients with colorectal cancer using random survival forest. J Gastrointest Cancer 2020. [PMID: 33174117 DOI: 10.1007/s12029-020-00544-3] [Reference Citation Analysis]
39 Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219 [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
40 Ding C, Luo J, Li L, Li S, Yang L, Pan H, Liu Q, Qin H, Chen C, Feng J. Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. J Exp Clin Cancer Res. 2016;35:5. [PMID: 26754532 DOI: 10.1186/s13046-015-0280-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
41 Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. J Intern Med 2013;274:1-24. [PMID: 23527888 DOI: 10.1111/joim.12070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]